<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104949</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000413703</org_study_id>
    <secondary_id>SWOG-S0346</secondary_id>
    <nct_id>NCT00104949</nct_id>
  </id_info>
  <brief_title>Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma</brief_title>
  <official_title>Phase II Study of Trastuzumab (NSC-688097) in Treatment of Locally Advanced or Metastatic Synovial Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Trastuzumab may also stop the&#xD;
      growth of tumor cells by blocking some of the enzymes needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well trastuzumab works in treating patients with&#xD;
      locally advanced or metastatic synovial sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate (confirmed complete response and partial response) in&#xD;
           patients with HER2/neu-overexpressing locally advanced or metastatic synovial sarcoma&#xD;
           treated with trastuzumab (Herceptin^®).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the frequency and severity of toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine overall survival and progression-free survival of patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Correlate, preliminarily, SYT-SSX translocation, HER2/neu expression, and monophasic and&#xD;
           biphasic phenotype with clinical outcomes in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a pilot, multicenter study.&#xD;
&#xD;
      Patients receive trastuzumab (Herceptin^®) IV over 90 minutes on day 1. Courses repeat every&#xD;
      21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 weeks until disease&#xD;
      progression and then every 6 months for up to 2 years from study entry.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 10-40&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (confirmed complete response and partial response)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 1 and 2 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 1 and 2 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed synovial sarcoma meeting 1 of the following stage criteria:&#xD;
&#xD;
               -  Locally advanced disease, defined as 1 of the following:&#xD;
&#xD;
                    -  Incurable by conventional multidisciplinary therapy, including surgery&#xD;
&#xD;
                    -  Surgically resectable only with significant morbidity&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Tumor HER2/neu positive (2+ or 3+) by immunohistochemistry&#xD;
&#xD;
          -  Tumor tissue must be available AND patient must be willing to allow specimen&#xD;
             submission&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No known CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 8 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and/or SGPT &lt; 1.5 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF &gt; 45% by MUGA&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No active gastrointestinal bleeding&#xD;
&#xD;
          -  No active inflammatory bowel disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated&#xD;
             stage I or II cancer in complete remission&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 60 days since prior radiotherapy to the target lesion*&#xD;
&#xD;
          -  No concurrent radiotherapy NOTE: *Lesion must have demonstrated disease progression&#xD;
             after completion of therapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 21 days since prior major surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 60 days since prior embolization or radiofrequency ablation to the target&#xD;
             lesion* NOTE: *Lesion must have demonstrated disease progression after completion of&#xD;
             therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest C. Borden, MD</last_name>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rashmi Chugh, MD</last_name>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George D. Demetri, MD</last_name>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret von Mehren, MD</last_name>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivien H.C. Bramwell, MB, BS, PhD, FRCP</last_name>
    <affiliation>Tom Baker Cancer Centre - Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen H. Albritton, MD</last_name>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>March 3, 2005</study_first_submitted>
  <study_first_submitted_qc>March 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2005</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>adult synovial sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

